Poschel B P, Ho P M, Ninteman F W, Callahan M J
Experientia. 1985 Sep 15;41(9):1153-6. doi: 10.1007/BF01951704.
Following oral or intravenous administration, a representative cognition activator drug, pramiracetam sulfate, is shown to have a pharmacologic therapeutic window at three different levels of study: learned behavior, gross EEG activity of the frontal cortex and hippocampus, and firing rate of single hippocampal neurons.
口服或静脉给药后，一种典型的认知激活药物硫酸普拉西坦在三个不同层面的研究中显示出药理学治疗窗口：学习行为、额叶皮质和海马体的总体脑电图活动以及单个海马体神经元的放电率。
